Sanofi Beats Taxotere Claims Over Post-2015 Hair Loss Warnings

About 200 users of Sanofi-Aventis US LLC‘s cancer drug Taxotere or generic equivalents will have their claims alleging permanent hair loss dismissed after a federal district court in Louisiana said the label adequately warned about that side effect after a December 2015 update.

The label referred to permanent hair loss in the “adverse reactions” section and two other places, clearly and consistently warning of the precise injury the plaintiffs allegedly suffered, the U.S. District Court for the Eastern District of Louisiana said.

The court rejected the plaintiffs’ argument that the label was nonetheless inadequate because permanent hair loss wasn’t ...